Innate Pharma S.A. (0EVI)
London Stock Exchange · UK · prices in EUR · close of 27 Oct 2026
Key indicators
| Last close | EUR 1.265 |
|---|---|
| 52-week range | 1.040 – 2.330 |
| Return, 1 month / 3 months | −12.4% / −22.7% |
| Return, 1 year / 3 years | −32.4% / −44.5% |
| Trend | Below its 200-day average |
| RSI (14) | 36 |
| Volatility (1 year) | 65.3% |
| Worst drawdown (1 year) | -43.5% |
| Average daily value traded | 0.04M EUR |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Innate Pharma is a clinical-stage biopharmaceutical company based in France that develops antibody-based treatments for cancer. Its work centres on immunotherapies designed to harness the body's immune system against tumours, with drug candidates studied in blood cancers and solid tumours. The company carries out its own research and also works with larger pharmaceutical partners on the development of its programmes. Its customers are chiefly the clinical and research institutions and corporate collaborators involved in testing and advancing these experimental medicines.
The shares are listed on the London Stock Exchange in UK under the code 0EVI, and the price on this page is in euros (EUR). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Innate Pharma S.A. (0EVI) trades on the London Stock Exchange in UK. It last closed at EUR 1.265 on 27 October 2026.
Its price-based Market X-Ray is 27 out of 100 (a weak price profile), ranking 3,174 of 3,788 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 32.4% and over the last three months it fell 22.7%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Stock Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 32 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -14.6% | ||
| From 52-week high | -42.6% | ||
| Momentum | 32 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -22.7% | ||
| 6-month return | 9.4% | ||
| 12-month return, skipping the last month | -22.9% | ||
| Stability (higher is calmer) | 22 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 65.3% | ||
| Worst drawdown, 1 year (smaller is calmer) | -43.5% | ||
| Liquidity | 21 · Weak | Thinly traded: prices can jump and exits can be hard. | |
| Average daily value traded | 0.04M EUR | ||
| Zero-volume days | 13.3% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 0 |
Strengths
No lens stands out as a clear strength against its exchange.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
- Stability (higher is calmer): Volatile, with deep drawdowns.
- Liquidity: Thinly traded: prices can jump and exits can be hard.
Returns
| 1 week | −5.5% |
|---|---|
| 1 month | −12.4% |
| 3 months | −22.7% |
| 6 months | +9.4% |
| 1 year | −32.4% |
| 3 years | −44.5% |
| 5 years | −73.7% |
Signals
| 50-day / 200-day average | 1.526 / 1.482 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.378 |
Technical summary
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Stock Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.